Leon R. Mcfarlane

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Systems vaccinology analysis of saRNA immunization identifies an acute innate immune signature correlated with adaptive immunity.

Systems vaccinology analysis of saRNA immunization identifies an acute innate immune signature correlated with adaptive immunity.

Journal: Molecular therapy. Advances
Published: September 26, 2025

HIV-1 envelope trimer vaccine induces sex-associated differences in antibody responses: a phase 1 clinical trial.

HIV-1 envelope trimer vaccine induces sex-associated differences in antibody responses: a phase 1 clinical trial.

Journal: Nature communications
Published: May 14, 2025

Safety and Immunogenicity of a Modified Self-Amplifying Ribonucleic Acid (saRNA) Vaccine Encoding SARS-CoV-2 Spike Glycoprotein in SARS-CoV-2 Seronegative and Seropositive Ugandan Individuals.

Safety and Immunogenicity of a Modified Self-Amplifying Ribonucleic Acid (saRNA) Vaccine Encoding SARS-CoV-2 Spike Glycoprotein in SARS-CoV-2 Seronegative and Seropositive Ugandan Individuals.

Journal: Vaccines
Published: March 17, 2025

Experimental medicine study with stabilised native-like HIV-1 Env immunogens drives long-term antibody responses, but lacks neutralising breadth.

Experimental medicine study with stabilised native-like HIV-1 Env immunogens drives long-term antibody responses, but lacks neutralising breadth.

Journal: EBioMedicine
Published: April 26, 2024

An investigation of trachoma vaccine regimens by the chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02): a phase 1, double-blind trial.

An investigation of trachoma vaccine regimens by the chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02): a phase 1, double-blind trial.

Journal: The Lancet. Infectious diseases
Published: November 13, 2023

Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study.

Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study.

Journal: EClinicalMedicine
Published: July 13, 2023

Profound structural conservation of chemically cross-linked HIV-1 envelope glycoprotein experimental vaccine antigens.

Profound structural conservation of chemically cross-linked HIV-1 envelope glycoprotein experimental vaccine antigens.

Journal: NPJ vaccines
Published: December 09, 2022

COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2.

COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2.

Journal: EClinicalMedicine
Published: September 26, 2022

Comparison of blood and lymph node cells after intramuscular injection with HIV envelope immunogens.

Comparison of blood and lymph node cells after intramuscular injection with HIV envelope immunogens.

Journal: Frontiers in immunology
Published: July 11, 2022

Enhanced immune responses following heterologous vaccination with self-amplifying RNA and mRNA COVID-19 vaccines.

Enhanced immune responses following heterologous vaccination with self-amplifying RNA and mRNA COVID-19 vaccines.

Journal: PLoS pathogens
Published: May 18, 2022

Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial.

Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial.

Journal: EClinicalMedicine
Published: July 28, 2021

Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.

Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.

Journal: The Lancet. Infectious diseases
Published: March 08, 2019
Showing 1-12 of 14

Last Updated: 09/26/2026